ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE, Inc., (www.sanuwave.com) an emerging leader in the development and commercialization of noninvasive, biologic response activating devices in the regenerative medicine segment, has added Southern Arizona VA in Tucson, Arizona as the newest clinical trial site for its Investigational Device Exemption (IDE) clinical trial evaluating Pulsed Acoustic Cellular Expression (“PACE™”) technology and the safety and efficacy of dermaPACE™ in healing diabetic foot ulcers. Dr. Katherine Neiderer will be the Principal Investigator for the site.
